Zachary A. Curry

Zachary A. Curry

Auto-generated profile, based on publicly available information

Zachary A. Curry

Department of Physical Medicine & Rehabilitation, Spaulding Rehabilitation Hospital, 300 1st Avenue, Charlestown, MA 02129, USA; Rehabilitation Outcomes Center at Spaulding, Spaulding Rehabilitation, 300 1st Avenue, Charlestown, MA 02129, USA; Department of Physical Medicine and Rehabilitation, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2017 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
GDGiulia Donvito
Giulia Donvito
SNSara Nass
Sara Nass
JWJenny Wilkerson
Jenny Wilkerson
ZCZachary A Curry
Zachary A Curry
LSLesley D Schurman
Lesley D Schurman
ALAron H Lichtman
Aron H Lichtman
A great need exists for the development of new medications to treat pain resulting from various disease states and types of injury. Given that the endogenous cannabinoid (that is, endocannabinoid) system modulates neuronal and immune cell function, both of which play key roles in pain, therapeutics targeting this system hold promise as novel analgesics. Potential therapeutic targets include the cannabinoid receptors, type 1 and 2, as well as biosynthetic and catabolic enzymes of the endocannabinoids N-arachidonoylethanolamine and 2-arachidonoylglycerol. Notably, cannabinoid receptor agonists as well as inhibitors of endocannabinoid-regulating enzymes fatty acid amide hydrolase and monoacylglycerol lipase produce reliable antinociceptive effects, and offer opioid-sparing antinociceptive effects in myriad preclinical inflammatory and neuropathic pain models. Emerging clinical studies show that ‘medicinal’ cannabis or cannabinoid-based medications relieve pain in human diseases such as cancer, multiple sclerosis, and fibromyalgia. However, clinical data have yet to demonstrate the analgesic efficacy of inhibitors of endocannabinoid-regulating enzymes. Likewise, the question of whether pharmacotherapies aimed at the endocannabinoid system promote opioid-sparing effects in the treatment of pain reflects an important area of research. Here we examine the preclinical and clinical evidence of various endocannabinoid system targets as potential therapeutic strategies for inflammatory and neuropathic pain conditions.

1 July 2018 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
ZCZachary A. Curry
Zachary A. Curry
JWJenny Wilkerson
Jenny Wilkerson
DBDeniz Bagdas
Deniz Bagdas
SKS. Lauren Kyte
S. Lauren Kyte
NPNipa Patel
Nipa Patel
ALAron H. Lichtman
Aron H. Lichtman
Although paclitaxel effectively treats various cancers, its debilitating peripheral neuropathic pain side effects often persist long after treatment has ended. Therefore, a compelling need exists for the identification of novel pharmacologic strategies to mitigate this condition. As inhibitors of monoacylglycerol lipase (MAGL), the primary hydrolytic enzyme of the endogenous cannabinoid, 2-arachidonyolglycerol, produces antinociceptive effects in numerous rodent models of pain, we investigated whether inhibitors of this enzyme (i.e., JZL184 and MJN110) would reverse paclitaxel-induced mechanical allodynia in mice. These drugs dose dependently reversed allodynia with respective ED50 values (95% confidence limit) of 8.4 (5.2–13.6) and 1.8 (1.0–3.3) mg/kg. Complementary genetic and pharmacologic approaches revealed that the antiallodynic effects of each drug require both cannabinoid receptors, CB1 and CB2. MJN110 reduced paclitaxel-mediated increased expression of monocyte chemoattractant protein-1 (MCP-1, CCL2) and phospho-p38 MAPK in dorsal root ganglia as well as MCP-1 in spinal dorsal horn. Whereas the antinociceptive effects of high dose JZL184 (40 mg/kg) underwent tolerance following 6 days of repeated dosing, repeated administration of a threshold dose (i.e., 4 mg/kg) completely reversed paclitaxel-induced allodynia. In addition, we found that the administration of MJN110 to control mice lacked intrinsic rewarding effects in the conditioned place preference (CPP) paradigm. However, it produced a CPP in paclitaxel-treated animals, suggesting a reduced paclitaxel-induced aversive state. Importantly, JZL184 did not alter the antiproliferative and apoptotic effects of paclitaxel in A549 and H460 non-small cell lung cancer cells. Taken together, these data indicate that MAGL inhibitors reverse paclitaxel-induced neuropathic pain without interfering with chemotherapeutic efficacy.

2 September 2018 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
MHMichael S. Heath
Michael S. Heath
DSDev R. Sahni
Dev R. Sahni
ZCZachary A. Curry
Zachary A. Curry
Steven R. FeldmanSteven R. Feldman
Steven R. Feldman
Introduction: Psoriasis is a prevalent cutaneous condition with severe physical and psychological manifestations. Since the advent of biologics, clinical outcomes in psoriasis have improved. However, retinoids are useful in the correct clinical context. Tazarotene and acitretin are currently the only US Food and Drug Administration approved retinoids for treatment of psoriasis. Both topical tazarotene and oral acitretin act on retinoic acid receptors and retinoid-X-receptors, resulting in altered gene expression of inflammatory cytokines and inhibition of keratinocyte proliferation. Areas covered: This article provides an in-depth pharmacologic and clinical review on the use of tazarotene and acitretin in psoriasis. The PubMed database was searched using combinations of keywords: acitretin, bioavailability, dosing, efficacy, etretinate, interactions, mechanism, pharmacodynamics, pharmacokinetics, pharmacogenetics, psoriasis, safety, tazarotene, tolerability, and toxicity. Expert opinion: Tazarotene and acitretin are effective treatments for psoriasis. Benefits include lack of immunosuppression and success treating inflammatory psoriasis. When combined with other topical and systemic agents, both retinoids improve clinical efficacy while lowering the treatment threshold. However, topical adherence and bothersome side effects can limit retinoid use. Acitretin and tazarotene both improve outcomes through a unique mechanism that especially benefits subsets of patients, despite side effects and limitations.

8 March 2018 in Pain
Verified
Journal Article
Closed access
JWJenny Wilkerson
Jenny Wilkerson
ZCZachary A. Curry
Zachary A. Curry
PKPamela D. Kinlow
Pamela D. Kinlow
BMBrittany L. Mason
Brittany L. Mason
KHKu-Lung Hsu
Ku-Lung Hsu
ALAron H. Lichtman
Aron H. Lichtman
A great need exists for the identification of new effective analgesics to treat sustained pain. However, most preclinical nociceptive assays measure behavioral responses evoked by noxious stimuli (ie, pain-stimulated behavior), which presents a challenge to distinguish between motor impairing and antinociceptive effects of drugs. Here, we demonstrate that chronic constriction injury (CCI) of the sciatic nerve elicits common pain-stimulated responses (ie, mechanical allodynia and thermal hyperalgesia) as well as reduces marble burying/digging behaviors that occur during the early stages of the neuropathy and resolve within 1 week. Although drugs representing distinct classes of analgesics (ie, morphine, valdecoxib, and gabapentin) reversed both CCI-induced and CCI-depressed nociceptive measures, diazepam lacked antinociceptive effects in all assays and the kappa-opioid receptor agonist U69593 reversed pain-stimulated, but not pain-depressed behaviors. In addition, we tested drugs targeting distinct components of the endocannabinoid system, including agonists at cannabinoid receptors type 1 (CB1) and type 2 (CB2), as well as inhibitors of the endocannabinoid-regulating enzymes fatty acid amide hydrolase and monoacylglycerol lipase. Each of these drugs reversed all CCI-induced nociceptive measures, with the exception of the fatty acid amide hydrolase inhibitor that reversed pain-stimulated behaviors, only. These findings support the use of the mouse marble-burying assay as a model of pain-depressed behavior within the first week of sciatic nerve injury to examine candidate analgesics. These data also support existing preclinical research that cannabinoid receptor agonists and inhibitors of endocannabinoid-regulating enzymes merit consideration for the treatment of pain.

3 December 2018 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
ZCZachary A. Curry
Zachary A. Curry
MJMatthew C. Johnson
Matthew C. Johnson
EUEmily L. Unrue
Emily L. Unrue
Steven R. FeldmanSteven R. Feldman
Steven R. Feldman
Background: Caregivers are often apprehensive about treating their child’s atopic dermatitis with a topical corticosteroid. Typical concerns include anxiety regarding side effects and the perceived burden of treatment. The perception of burden may be modifiable through anchoring. Objective: To evaluate caregivers’ willingness to treat their child’s atopic dermatitis with a topical corticosteroid once-daily if initially anchored to the idea of a four-times-daily treatment regimen. Methods: A prospective survey study was performed in 100 caregivers of children with atopic dermatitis. Scores were treated as ordinal data and evaluated using the Mann-Whitney U test and chi-squared test. Results: Of the 100 recruited participants, 97 were eligible and returned completed surveys. Subjects anchored to a four-times-daily treatment regimen were more willing to treat their child’s atopic dermatitis once-daily (mean, 8.7) than those not anchored (mean, 7.9), however the difference between these groups was not statistically significant (P = 0.173). Conclusions: Caregivers reported being generally quite willing to apply topical corticosteroids once-daily. Anchoring was associated with a slightly higher score, though it was not statistically significant. For most patients with atopic dermatitis, anchoring may not be helpful, but for patients whose main barrier is perceived burdensomeness of treatment, anchoring may be of some benefit.

30 April 2024 in American Journal of Physical Medicine & Rehabilitation
Verified
Journal Article
Closed access
ZCZachary A. Curry
Zachary A. Curry
MAMichael N. Andrew
Michael N. Andrew
MCMichael C. Chiang
Michael C. Chiang
RGRichard Goldstein
Richard Goldstein
RZRoss Do Zafonte
Ross Do Zafonte
JSJeffrey C. Schneider
Jeffrey C. Schneider
Objective: Pain is common in inpatient rehabilitation patients; however, the prevalence of pain diagnoses in this population is not well-defined. This study examines comorbid pain diagnoses in inpatient rehabilitation patients across impairment groups. Design: Adult inpatient rehabilitation patients discharged from January 2016 through December 2019 were identified in the Uniform Data System for Medical Rehabilitation database using a literature-established framework containing International Classification of Diseases, Tenth Revision, Clinical (ICD-10-CM) pain diagnoses. Demographic data, clinical data, and pain diagnoses were compared across the 17 rehabilitation impairment groups. Results: Of 1,925,002 patients identified, 1,347,239 (70.0%) had at least one International Classification of Diseases, Tenth Revision (ICD-10) pain diagnosis. Over half of all patients in each impairment group had at least one pain diagnosis. The most common pain diagnoses were limb/extremity and joint pain, with variation between impairment groups. Female sex and being in the arthritis, major multiple trauma, and pain syndrome impairment groups were associated with a greater odds of a pain diagnosis. Conclusions: Over half of all patients in each rehabilitation impairment group have a pain diagnosis, which varies between impairment groups. Because of the high prevalence of pain diagnoses, a new focus on pain management in inpatient rehabilitation patients is needed. Rehabilitation outcomes may also be affected by pain.